Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
Details : Gadoterate Meglumine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 10, 2020
Lead Product(s) : Gadoterate Meglumine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable